We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Distribución de los niveles séricos de amilasa en pacientes con leishmaniasis cutánea en tratamiento con antimoniato de meglumina.
- Authors
RODRíGUEZ, ÁNGELA JOHANNA; MACíAS, EVA LUCíA
- Abstract
The treatment of choice for leishmaniasis is meglumine antimoniate, reporting effects at the pancreatic duct. A study with 90 patients between August 2010 and April 2011 found amylase changes at the beginning, middle and end of treatment at doses of 20 mg/kg/ day. The averages were: weight, 68 kg±9.1, age 24.73±4.45 years, and 28.15±3.97 g of the drug dose. The site of injury was 44,4% in upper limbs. No significant association was found between the variables weight, age and treatment programs. Alteration was present in 49,37% in the middle of treatment and 6,5% at the end. There were significant differences in reported half-amylase treatment on the two doses (p=0,000). In conclusion, control must be performed in serum amylase and rising especially in the middle of treatment.
- Subjects
SERUM; AMYLASES; LEISHMANIASIS; DRUGS; EXTREMITIES (Anatomy)
- Publication
Universitas Médica, 2012, Vol 53, Issue 1, p33
- ISSN
0041-9095
- Publication type
Article